Arvinas Q2 2026: Revenue Hits $249.7M, Net Income $169.4M, and Cash Runway Extended to H2 2028
ARVN sits 39% above its 52-week low of $6.055.
Summary
Driven by the VEPPANU licensing deal, Arvinas reported Q2 2026 revenue of $249.7M and net income of $169.4M. Cash runway extends to H2 2028, and the company outlined multiple near-term clinical data milestones.
Key Events · Earnings and Guidance · ARVN
-
Q2 Revenue Surges to $249.7M
Revenue jumped from $22.4M a year ago, primarily due to $62.5M from the Rigel license agreement, a $50M milestone payment for VEPPANU approval, and $112.6M from the Pfizer collaboration.
-
Net Income of $169.4M
Arvinas swung to a $169.4M net profit from a $61.2M loss in Q2 2025, driven by the licensing revenue and lower R&D expenses.
-
Cash Runway Extended to H2 2028
Cash, equivalents, and marketable securities totaled $567.9M as of June 30, 2026, down from $685.4M at year-end 2025, but sufficient to fund operations into the second half of 2028.
-
Three Phase 1 Data Readouts in Next 12 Months
Arvinas plans to share clinical data from ARV-393 (BCL6 degrader), ARV-102 (LRRK2 degrader), and ARV-027 (polyQ-AR degrader) over the next year, with ARV-393 data expected at a medical congress in H2 2026.
Analysis · ARVN · Life Sciences
A strong quarter for Arvinas was fueled by the VEPPANU licensing deal with Rigel, which contributed $62.5M in license revenue and a $50M milestone payment. The company swung to a $169.4M net profit from a year-ago loss, and cash reserves of $567.9M now fund operations into the second half of 2028. The pipeline is advancing with three Phase 1 data readouts expected over the next 12 months and a new immuno-oncology trial starting this quarter. While this quarter marks a financial inflection point, the real value driver remains the clinical pipeline — investors will watch for the upcoming data catalysts.
At the time of this filing, ARVN was trading at $8.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $520M. The 52-week trading range was $6.06 to $14.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.